References
- Pizzo PA. Empirical therapy and prevention of infection in immunocompromised host. In: Mandell GL, Bennett JE, Dolin R eds. Principles and practice of infectious diseases. New York: Churchill Livingstone Inc., 1995: 2686-96.
- Calandra T, Cometta A. Antibiotic therapy for Gram-negative bacteremia. Infect Dis Clin N Am 1991; 5: 817–34.
- Pizzo PA. Management of fever in patients with cancer and treatment - induced neutropenia. N Engl J Med 1993; 328: 1323–32.
- Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13 (Jan): 165-76.
- The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185–200.
- Engervall P, Kahn M, Dornbusch K, Bjorkholm M. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial. J Chemother 1999; 11 (4): 278–86.
- Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neu-tropenic cancer patients. Ann Hematol 2000; 79 (March): 152-7.
- EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-nega-tive bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–8.
- Love LJ, Schimpff SC, Schiffer CA. Improved prognosis for granulocytopenic patients with Gram-negative bacteremia. Am J Med 1980; 68: 643–8.
- Leyland MJ, Bayston KF, Cohen J, et al. A compara-tive study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30 (June): 843-54.
- Liang R, Yung R, Chiu E et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neu-tropenic patients. Antimicrob Agents Chemother 1990; 34: 1336–41.
- Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D. A randomized trial comparing cef-tazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8.
- Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of The European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologicie Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40 (May): 1108-15.
- Immunocompromised Host Society. The design, analy-sis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397–401.
- Vazquez L, Encinas MP, Mann LS, et al. Randomized prospective study comparing cost-effectiveness teicoplanin and vancomycin as second-line empiric therapy infection in neu-tropenic patients. Haematologica 1999; 84 (March): 231-6.